Belpointe Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Belpointe Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-893	Closed	-$131K	–	1996
2023 Q1	$131K	Sell	893 -463	-34%	-$68.5K	0.01%	1163
2022 Q4	$216K	Buy	+1,356	New	+$199K	0.01%	865
2022 Q1	–	Sell	-8,096	Closed	-$1.03M	–	1264
2021 Q4	$1.03M	Buy	+8,096	New	+$1.06M	0.06%	309
2021 Q3	–	Sell	-3,146	Closed	-$559K	–	1217
2021 Q2	$559K	Buy	+3,146	New	+$545K	0.04%	465
2020 Q1	–	Sell	-1,348	Closed	-$201K	–	710
2019 Q4	$201K	Buy	+1,348	New	+$183K	0.03%	537

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Belpointe Asset Management's JAZZ Position: Q2 2023 in Review

Belpointe Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2023, closing a stake of 893 shares — an estimated $131K sold.

Belpointe Asset Management first reported a position in JAZZ in Q4 2019 and held it in 5 quarters. The position peaked at $1.03M in Q4 2021. 471 funds tracked by Wall St. Rank hold JAZZ as of Q2 2023.

Belpointe Asset Management reported no remaining Jazz Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 893 Jazz Pharmaceuticals shares in Q2 2023, an estimated $131K.
Belpointe Asset Management first reported a position in Jazz Pharmaceuticals in Q4 2019 and held it in 5 quarters.
Belpointe Asset Management's Jazz Pharmaceuticals position peaked at $1.03M in Q4 2021.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.